Prevalence and cost of nonadherence to antiepileptic drugs in elderly patients with epilepsy

Epilepsy and Behavior

Volumn 14, Issue 2, 2009, Pages 324-329

  Ettinger, Alan B ^a   Manjunath, Ranjani ^b   Candrilli, Sean D ^c   Davis, Keith L ^c  

^a LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^b GLAXOSMITHKLINE   (United States)

^c RTI HEALTH SOLUTIONS   (United States)

Author keywords

Adherence; Antiepileptic drugs; Claims data; Costs; Elderly

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

AGED; ARTICLE; CONTROLLED STUDY; DRUG COST; DRUG UTILIZATION; ELDERLY CARE; EMERGENCY WARD; EPILEPSY; FEMALE; HEALTH CARE COST; HEALTH INSURANCE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PREVALENCE;

AGED; ANTICONVULSANTS; EPILEPSY; FEMALE; GERIATRIC ASSESSMENT; HEALTH CARE COSTS; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; LINEAR MODELS; MALE; MEDICATION ADHERENCE; PREVALENCE; RETROSPECTIVE STUDIES;

EID: 59749100642     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2008.10.021     Document Type: Article

References (25)

1. Hauser W.A., Annegers J.F., and Kurland L.T. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota. Epilepsia 34 (1993) 453-468
2. Hauser W.A. Epidemiology of seizures and epilepsy in the elderly. In: Rowan A.J., and Ramsay R.E. (Eds). Seizures and epilepsy in elderly (1997), Butterworth-Heinemann, Boston 7-18
3. Collins N.S., Shapiro R.A., and Ramsay R.E. Elders with epilepsy. Med Clin North Am 90 (2006) 945-966
4. Korn-Lubetzki I., Steiner-Birmanns B., Galperin I., Benasouli Y., and Steiner I. Nonconvulsive status epilepticus in older people: a diagnostic challenge and a treatable condition. J Am Geriatr Soc 55 (2007) 1475-1476
5. Uthman B., and Bearden S. Rhythmic diffuse delta frequency activity presenting as an unusual EEG correlate of nonconvulsive status epilepticus: three case studies. Epilepsy Behav 12 (2008) 191-199
6. Green L.W., and Simons-Morton D.G. Denial, delay, and disappointment: discovering and overcoming the causes of drug errors and missed appointments. In: Schmidt D., and Leppik I.E. (Eds). Compliance in epilepsy (1988), Elsevier, New York 7-21
7. Leppik I.E. How to get patients with epilepsy to take their medication: the problem of noncompliance. Postgrad Med 88 (1990) 253-256
8. Jones R.M., Butler J.A., Thomas V.A., Peveler R.C., and Prevett M. Adherence to treatment in patients with epilepsy: associations with seizure control and illness beliefs. Seizure 15 (2006) 504-508
9. Davis K.L., Candrilli S.D., and Edin H.M. Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population. Epilepsia 49 (2008) 446-454
10. Lackner T.E. Strategies for optimizing antiepileptic drug therapy in elderly people. Pharmacotherapy 22 (2002) 329-364
11. Neufeld M.Y., Vishne T., Chistik V., and Korczyn A.D. Life-long history of injuries related to seizures. Epilepsy Res 34 (1999) 123-127
12. Biton V., Gates J.R., and Sussman Ld. Prolonged postictal encephalopathy. Neurology 40 (1990) 963-966
13. Charlson M.E., Pompei P., Ales K.L., and McKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 40 (1987) 373-383
14. Andrade S.E., Kahler K.H., Frech F., and Chan K.A. Methods for evaluation of medication adherence using automated databases. Pharmacoepidemiol Drug Saf 15 (2006) 565-574
15. Grosset K.A., Bone I., and Grosset D.G. Suboptimal medication adherence in Parkinson's disease. Mov Disord 20 (2005) 1502-1507
16. Grosset K.A., Reid J.L., and Grosset D.G. Medicine-taking behavior: implications of suboptimal compliance in Parkinson's disease. Mov Disord 20 (2005) 1397-1404
17. Rascol O., Brooks D.J., Brunt E.R., Amos D.K., Poewe W.H., and Stocchi F. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study-056 study group. Mov Disord 13 (1998) 39-45
18. Hughes D.A., Bagust A., Haycox A., and Walley T. Accounting for non-compliance in pharmacoeconomic evaluations. Pharmacoeconomics 19 (2001) 1185-1197
19. Shaya F.T., El Khoury A.C., Wong W., et al. Persistence with pharmacotherapy for gastrointestinal disease: associated costs of health care. P&T 31 (2006) 657-665
20. Gilmer T.P., Dolder C.R., Lacro J.P., et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 161 (2004) 692-699
21. Sokol M.C., McGuigan K.A., Verbrugge R.R., et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 43 (2005) 521-530
22. Bender B.G., and Rand C. Medication non-adherence and asthma treatment cost. Curr Opin Allergy Clin Immunol 4 (2004) 191-195
23. Sikka R., Xia F., and Aubert R.E. Estimating medication persistency using administrative claims data. Am J Manag Care 11 (2005) 449-457
24. Losina E., Barrett J., Baron J.A., and Katz J.N. Accuracy of Medicare claims data for rheumatologic diagnoses in total hip replacement recipients. J Clin Epidemiol 56 (2003) 515-519
25. Newcomer R., Clay T., Luxenberg J.S., and Miller R.H. Misclassification and selection bias when identifying Alzheimer's disease solely from Medicare claims records. J Am Geriatr Soc 47 (1999) 215-219